ClinicalTrials.gg
CompletedNCT00528606CORD-IUpdated Dec 2, 2017Results posted

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

A Phase 3 interventional study of collagenase clostridium histolyticum and Placebo in Dupuytren's Contracture, sponsored by Endo Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.

Enrollment
3rd of 17
308 · median 76
Started
2007
with 1 other
Phase 3
7 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
6 of 17
Endo Pharmaceuticals

Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 3rd largest by enrollment, is one of 2 that started in 2007, is one of 7 in phase 3, and was the 2nd registered.

Dupuytren Contracture

78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.

Browse Dupuytren Contracture studies →

Open to participants now

None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Microbial Collagenase in Dupuytren Contracture as a file.
02

Study summary

This was a Phase 3, double-blind, randomized, placebo-controlled study conducted in the United States. Subjects with a diagnosis of Dupuytren's contracture in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint that resulted in a fixed flexion deformity of at least one finger, other than the thumb, that was at least 20° as measured by finger goniometry and was suitable for injection were randomized 2:1 to receive AA4500 0.58 mg or placebo.

This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.

03

Conditions studied

  • Dupuytren's Contracture

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of Dupuytren's contracture, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100°, for MP (80° for PIP) joints, caused by a palpable cord that had never been treated with AA4500.
  • Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
  • Judged to be in good health.

Exclusion criteria

Exclusion Criteria:

  • Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
  • Had received a treatment for Dupuytren's contracture, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.
  • Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    AA4500 0.58 mg

    Biological: collagenase clostridium histolyticum

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.

    Also known as: XIAFLEX®, AA4500

  • BiologicalPlacebo

    Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.

06

What researchers measure

Primary outcomes

  1. Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection

    The Primary Outcome Measure for patients treated with AA4500 is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection. The Primary Outcome Measure for placebo treated patients is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

    Time frame: Within 30 days after the last injection

Secondary outcomes

  1. Clinical Improvement After the Last Injection

    Clinical Improvement is defined as \>= 50% reduction from baseline in degree of contracture within 30 days of the injection.

    Time frame: Baseline; within 30 days after the last injection

  2. Percent Reduction From Baseline Contracture After the Last Injection

    Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.

    Time frame: Baseline; within 30 days after the last injection

  3. Change From Baseline Range of Motion After the Last Injection

    Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.

    Time frame: Baselin; within 30 days after the last injection

  4. Time to First Achieve Success After the Last Injection

    Time frame: Last evaluation visit on which clinical success is achieved through the Day 30 evaluation

  5. Clinical Success (Reduction in Contracture to 5° or Less) After the First Injection

    Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.

    Time frame: Within 30 days after first injection

  6. Clinical Improvement After the First Injection

    Clinical Improvement is defined as \>= 50% reduction from contracture within 30 days of the first injectionor greater of baseline contracture within 30 days of the injection.

    Time frame: Baseline; within 30 days after the first injection

  7. Percent Reduction From Baseline Contracture After the First Injection

    Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.

    Time frame: Baseline, within 30 days after the first injection

  8. Change From Baseline Range of Motion After the First Injection

    Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.

    Time frame: Baseline; within 30 days after the first injection

07

Results

Posted Oct 22, 2010

Participant flow

Participant flow — Overall Study
MilestoneAA4500 0.58 mgPlacebo
Started204104
Completed191100
Not completed134
Withdrew: Withdrew consent43
Withdrew: Lost to follow-up41
Withdrew: Adverse event30
Withdrew: Other20

Outcome measures

PrimaryClinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection

The Primary Outcome Measure for patients treated with AA4500 is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection. The Primary Outcome Measure for placebo treated patients is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

Time frame:
Within 30 days after the last injection
Reported as:
Number · Percentage of Joints
Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection
Percentage of JointsAA4500 0.58 mgPlacebo
Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection646.8
Statistical analysis
  • AA4500 0.58 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001
SecondaryClinical Improvement After the Last Injection

Clinical Improvement is defined as \>= 50% reduction from baseline in degree of contracture within 30 days of the injection.

Time frame:
Baseline; within 30 days after the last injection
Reported as:
Number · Percentage of Joints
Clinical Improvement After the Last Injection
Percentage of JointsAA4500 0.58 mgPlacebo
Clinical Improvement After the Last Injection84.711.7
SecondaryPercent Reduction From Baseline Contracture After the Last Injection

Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.

Time frame:
Baseline; within 30 days after the last injection
Reported as:
Mean · Percent reduction from baseline
Percent Reduction From Baseline Contracture After the Last Injection
Percent reduction from baselineAA4500 0.58 mgPlacebo
Percent Reduction From Baseline Contracture After the Last Injection79.3 ± 32.588.6 ± 30.78
SecondaryChange From Baseline Range of Motion After the Last Injection

Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.

Time frame:
Baselin; within 30 days after the last injection
Reported as:
Mean · degrees
Change From Baseline Range of Motion After the Last Injection
degreesAA4500 0.58 mgPlacebo
Change From Baseline Range of Motion After the Last Injection36.70 ± 21.014.0 ± 14.77
SecondaryTime to First Achieve Success After the Last Injection
Time frame:
Last evaluation visit on which clinical success is achieved through the Day 30 evaluation
Reported as:
Number · percentage of joints
Time to First Achieve Success After the Last Injection
percentage of jointsAA4500 0.58 mgPlacebo
Injection 1, Day 112.80.0
Injection 1, Day 712.30.0
Injection 1, Day 3014.31.0
Injection 2, Day 00.50.0
Injection 2, Day 14.90.0
Injection 2, Day 75.40.0
Injection 2, Day 306.41.0
Injection 3, Day 00.00.0
Injection 3, Day 12.00.0
Injection 3, Day 72.50.0
Injection 3, Day 302.54.9
Day 900.50.0
Did not reach clinical success by last injection36.093.2
SecondaryClinical Success (Reduction in Contracture to 5° or Less) After the First Injection

Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.

Time frame:
Within 30 days after first injection
Reported as:
Number · Percentage of Joints
Clinical Success (Reduction in Contracture to 5° or Less) After the First Injection
Percentage of JointsAA4500 0.58 mgPlacebo
Clinical Success (Reduction in Contracture to 5° or Less) After the First Injection38.91.0
SecondaryClinical Improvement After the First Injection

Clinical Improvement is defined as \>= 50% reduction from contracture within 30 days of the first injectionor greater of baseline contracture within 30 days of the injection.

Time frame:
Baseline; within 30 days after the first injection
Reported as:
Number · Percentage of Joints
Clinical Improvement After the First Injection
Percentage of JointsAA4500 0.58 mgPlacebo
Clinical Improvement After the First Injection67.52.9
SecondaryPercent Reduction From Baseline Contracture After the First Injection

Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.

Time frame:
Baseline, within 30 days after the first injection
Reported as:
Mean · Percent reduction from baseline
Percent Reduction From Baseline Contracture After the First Injection
Percent reduction from baselineAA4500 0.58 mgPlacebo
Percent Reduction From Baseline Contracture After the First Injection64.8 ± 34.604.7 ± 20.81
SecondaryChange From Baseline Range of Motion After the First Injection

Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.

Time frame:
Baseline; within 30 days after the first injection
Reported as:
Mean · degrees
Change From Baseline Range of Motion After the First Injection
degreesAA4500 0.58 mgPlacebo
Change From Baseline Range of Motion After the First Injection28.30 ± 20.231.50 ± 11.03

Adverse events

Collected over Non-serious adverse events (non-SAEs) were collected from time of study drug administration, serious adverse events (SAEs) were collected from time subject signed ICF. Non-SAEs & SAEs were collected until 30 days after completion or discharge from study.. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.58 mg—8/204 (3.9%)196/204 (96.1%)
Placebo—1/104 (1%)25/104 (24%)
Most frequent serious events
Most frequent serious events
EventAA4500 0.58 mgPlacebo
Tendon ruptureInjury, poisoning and procedural complications2/2040/104
Acute cholecystitisHepatobiliary disorders0/2041/104
Complex regional pain syndromeNervous system disorders1/2040/104
Ligament disorderMusculoskeletal and connective tissue disorders1/2040/104
Myocardial infarctionCardiac disorders1/2040/104
Panic attackPsychiatric disorders1/2040/104
Pelvi-ureteric obstructionRenal and urinary disorders1/2040/104
Spinal fusion surgerySurgical and medical procedures1/2040/104
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAA4500 0.58 mgPlacebo
Oedema peripheralGeneral disorders148/2044/104
ContusionInjury, poisoning and procedural complications104/2042/104
Injection site haemorrhageGeneral disorders76/2044/104
Injection site painGeneral disorders66/2045/104
Pain in extremityMusculoskeletal and connective tissue disorders65/2043/104
TendernessGeneral disorders54/2040/104
EcchymosisSkin and subcutaneous tissue disorders51/2041/104
Injection site swellingGeneral disorders43/2044/104
PruritusSkin and subcutaneous tissue disorders22/2041/104
Skin lacerationInjury, poisoning and procedural complications22/2040/104

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500 0.58 mgPlaceboTotal
<=18 years000
Between 18 and 65 years12057177
>=65 years8447131
Age, Continuous
Age, Continuous(years)AA4500 0.58 mgPlaceboTotal
Mean62.3 ± 9.763.3 ± 9.162.7 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.58 mgPlaceboTotal
Female333063
Male17174245
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AA4500 0.58 mgPlaceboTotal
White203104307
Hispanic101
Region of Enrollment
Region of Enrollment(participants)AA4500 0.58 mgPlaceboTotal
United States204104308
08

Study locations

15 sites
  • 100 UCLA Medical Plaza, Suite 305
    Los Angeles, California 90095, United States
  • Hand Surgery Clinic
    Palo Alto, California 94304, United States
  • Hand Surgery Associates, PC
    Denver, Colorado 80210, United States
  • The Hand and Upper Extremity Center of Georgia, P.C.
    Atlanta, Georgia 30342, United States
  • Rockford Orthopedic Associates, Ltd.
    Rockford, Illinois 61107, United States
  • The Indiana Hand Center
    Indianapolis, Indiana 46260, United States
  • Brigham and Women's Hospital, Department of Orthopedic Surgery
    Boston, Massachusetts 02115, United States
  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
  • TRIA Orthopaedic Center
    Minneapolis, Minnesota 55431, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • SUNY Stony Brook - Department of Orthopedics
    Stony Brook, New York 11794, United States
  • Health Research Institute
    Oklahoma City, Oklahoma 73109, United States
  • Hand Microsurgery & Reconstructive Orthopaedics
    Erie, Pennsylvania 16550, United States
  • University Orthopedics Center
    State College, Pennsylvania 16801, United States
  • Department of Orthopaedics, Brown University, Rhode Island Hospital
    Providence, Rhode Island 02905, United States
09

References and documents

Publications

  • Witthaut J, Bushmakin AG, Gerber RA, Cappelleri JC, Le Graverand-Gastineau MP. Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study. Clin Drug Investig. 2011 Nov 1;31(11):791-8. doi: 10.1007/BF03256918. PubMed 21967070 ↗
  • Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J; CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009 Sep 3;361(10):968-79. doi: 10.1056/NEJMoa0810866. PubMed 19726771 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2007 to primary completion in Apr 2008, 8 months.

Results were first posted in Oct 2010, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2007
First posted
Sep 12, 2007
StartActual
Aug 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Oct 22, 2010
Last update
Dec 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00528606
Responsible party
Sponsor
First posted
Sep 12, 2007
Start date
Aug 2007
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Oct 22, 2010
Last update
Dec 2, 2017

Study contacts

Veronica Urdaneta, MD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion